Veradermics, a Phase 3-ready biotech developing therapies for hair loss, raised $256 million by offering 15.1 million shares at $17, above the range of $14 to $16. The company had originally planned to offer 13.4 million shares. At pricing, Veradermics...read more
Updated Monday, 2/2. Eight IPOs raising at least $100 million are currently scheduled for the week ahead. If all eight deals price, it would be the busiest week for sizable offerings since 2021. Only one other week over the past four years has produced seven...read more
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, announced terms for its IPO on Wednesday. The New Haven, CT-based company plans to raise $200 million by offering 13.4 million shares at a price range of $14 to $16. At the midpoint of...read more
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Hair loss biotech Veradermics prices upsized IPO at $17, above the range
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, raised $256 million by offering 15.1 million shares at $17, above the range of $14 to $16. The company had originally planned to offer 13.4 million shares. At pricing, Veradermics...read more
US IPO Week Ahead: At least 8 sizable IPOs teed up in one of the busiest weeks in four years
Updated Monday, 2/2. Eight IPOs raising at least $100 million are currently scheduled for the week ahead. If all eight deals price, it would be the busiest week for sizable offerings since 2021. Only one other week over the past four years has produced seven...read more
Hair loss biotech Veradermics sets terms for $200 million IPO
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, announced terms for its IPO on Wednesday. The New Haven, CT-based company plans to raise $200 million by offering 13.4 million shares at a price range of $14 to $16. At the midpoint of...read more
US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more